Hyaluronic acid in the evaluation of liver fibrosis in patients with hepatitis C on haemodialysis
AUTOR(ES)
Ávila, Renata Eliane de, Carmo, Ricardo Andrade, Farah, Kátia de Paula, Teixeira, Antônio Lúcio, Coimbra, Lucas Viana, Antunes, Carlos MaurÃcio de Figueiredo, Lambertucci, José Roberto
FONTE
Brazilian Journal of Infectious Diseases
DATA DE PUBLICAÇÃO
2010-08
RESUMO
BACKGROUND: This study evaluated the role of HA as a marker of liver fibrosis in patients with hepatitis C on haemodialysis. METHODS: This is a cross-sectional study in which 52 patients were divided into two groups: Group 1: patients with hepatitis C and end-stage renal disease (ESRD) undergoing haemodialysis (n = 23); and Group 2: patients with hepatitis C without ESRD (n = 29). Plasma levels of HA were associated with histological data of the samples obtained by liver biopsy and classified by METAVIR group scoring system. RESULTS: Higher plasma levels were significantly correlated to significant liver fibrosis (METAVIR > F2). In Group 1, the HA cutoff to discriminate significant fibrosis was 984.8 ng/mL, with accuracy, sensitivity and specificity of 80.8%, 83.0%, and 70.0%, respectively. In Group 2, the HA cutoff was 222.3 ng/mL, with accuracy, sensitivity and specificity of 74.5%, 70.0%, and 94.0%, respectively. CONCLUSION: HA was an accurate noninvasive marker in predicting significant fibrosis in patients with hepatitis C on haemodialysis.
Documentos Relacionados
- Effect of host-related factors on the intensity of liver fibrosis in patients with chronic hepatitis C virus infection
- Role of hyaluronic acid and laminin as serum markers for predicting significant fibrosis in patients with chronic hepatitis B
- Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease
- Micronuclei formation in liver fibrosis samples from patients infected by hepatitis C virus
- Noninvasive means of diagnosing liver fibrosis in hepatitis C